Please assess the completion status of the following clinical trial:

Trial Title: An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults greater than or equal to (≥) 18 years of age~* Histologically or cytologically documented inoperable, locally advanced, metastatic, or recurrent NSCLC~* Previous treatment with no more than 2 prior chemotherapy regimens~Exclusion Criteria:~* Previous systemic anti-cancer therapy with human epidermal growth factor receptor 1 (HER1)/epidermal growth factor receptor (EGFR) inhibitors~* Inability to take oral medication~* Any other malignancies within 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib (Type: EXPERIMENTAL): Erlotinib will be given as a single agent in this expanded access program (EAP) to participants with inoperable, locally advanced, recurrent, or metastatic NSCLC. Treatment will continue until unacceptable toxicity, disease progression, or withdrawal for any other reason.

Based on this trial design, predict the completion outcome and termination type (if applicable).